Bayer submits aflibercept 8 mg for advertising and marketing and marketing authorization in Japan

01

March

2023

Abstract

Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (moist) age-associated macular degeneration (nAMD) and diabetic macular edema (DME) relies utterly mostly on certain outcomes of half III scientific trials, PULSAR and PHOTON / In both trials, aflibercept 8 mg demonstrated unheard of durability outcomes with remedy intervals of up to 16 weeks, with similar visible acuity as successfully as fast and resilient fluid control to the comparator Eylea^TM (aflibercept 2 mg) by to week forty eight / Security of aflibercept 8 mg used to be in step with the protection profile of Eylea (aflibercept 2 mg) / Extended remedy intervals with fewer injections addresses the most important affected person need